Screening a mushroom extract library for activity against Acinetobacter baumannii and Burkholderia cepacia and the identification of a compound with anti-Burkholderia activity

Annals of Clinical Microbiology and Antimicrobials

Volumn 9, Issue , 2010, Pages

  Schwan, William R ^a   Dunek, Craig ^a   Gebhardt, Michael ^a   Engelbrecht, Kathleen ^a   Klett, Tiffany ^a   Monte, Aaron ^a   Toce, Joseph ^a   Rott, Marc ^a   Volk, Thomas J ^a   LiPuma, John J ^b   Liu, Xue Ting ^a   McKelvey, Ronald ^a  

^a UNIVERSITY OF WISCONSIN LA CROSSE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOQUINOLINE; AMIKACIN; ANTIINFECTIVE AGENT; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; FUNGAL EXTRACT; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NATURAL PRODUCT; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TETRACYCLINE; TIMENTIN; TOBRAMYCIN; AMINOQUINOLINE DERIVATIVE;

ACINETOBACTER BAUMANNII; AGARICALES; ANIMAL CELL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOASSAY; BURKHOLDERIA CEPACIA; CONTROLLED STUDY; CYTOTOXICITY; DISK DIFFUSION; DRUG IDENTIFICATION; DRUG PURIFICATION; DRUG SCREENING; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUCOPAXILLUS ALBISSIMUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; SHEEP ERYTHROCYTE; TOXICITY TESTING; ANIMAL; CHEMISTRY; DRUG EFFECT; DRUG MIXTURE; ISOLATION AND PURIFICATION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MONOCYTE;

ACINETOBACTER BAUMANNII; AGARICALES; AMINOQUINOLINES; ANIMALS; ANTI-BACTERIAL AGENTS; BURKHOLDERIA CEPACIA; COMPLEX MIXTURES; DRUG EVALUATION, PRECLINICAL; MICE; MICROBIAL SENSITIVITY TESTS; MONOCYTES;

EID: 76949100562     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-9-4     Document Type: Article

References (32)

1. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev 1996, 9:148-165. 172888, 8964033.
2. Lyczak JB, Cannon CL, Pier GB. Lung infections associated with cystic fibrosis. Clin Microbiol Rev 2002, 15:194-222. 10.1128/CMR.15.2.194-222.2002, 118069, 11932230.
3. Quinn JP. Clinical problems posed by multiresistant nonfermenting gram-negative pathogens. Clin Infect Dis 1998, 27(Suppl 1):S117-S124. 10.1086/514912, 9710680.
4. Tablan OC, Chorba TL, Schidlow DV, White JW, Hardy KA, Gilligan PH, Morgan WM, Carson LA, Martone WJ, Jason JM, Jarvis WR. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985, 107:382-387. 10.1016/S0022-3476(85)80511-4, 4032134.
5. Vanlaere E, LiPuma JJ, Baldwin A, Henry D, Brandt ED, Mahenthiralingham E, Speert D, Dowson C, Vandamme P. Burkholderia latens sp. nov., Burkholderia diffusa sp. nov., Burkholderia arboris sp. nov., Burkholderia seminalis sp. nov., and Burkholderia metallica sp. nov.; five novel species within the Burkholderia cepacia complex. Int J Syst Evol Microbiol 2008, 58:1580-1590. 10.1099/ijs.0.65634-0, 18599699.
6. Vanlaere E, Baldwin A, Gevers D, Henry D, De Brandt E, LiPuma JJ, Mahenthiralingam E, Speert DP, Dowson C, Vandamme P. Taxon K complex within the Burkholderia cepacia complex, comprises at least two novel species, Burkholderia contaminans sp. nov. and Burkholderia lata sp. nov. Int J Syst Evol Microbiol 2009, 59:102-111. 10.1099/ijs.0.001123-0, 19126732.
7. Coenye T, Vandamme O, Govan JR, LiPuma JJ. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001, 39:3427-3436. 10.1128/JCM.39.10.3427-3436.2001, 88367, 11574551.
8. Reik R, Spilker T, LiPuma JJ. Distribution of Burkholderia cepacia complex species among isolates recovered from persons with or without cystic fibrosis. J Clin Microbiol 2005, 43:2926-2928. 10.1128/JCM.43.6.2926-2928.2005, 1151955, 15956421.
9. Holmes A, Nolan R, Taylor R, Finley R, Riley M, Jiang RZ, Steinbach S, Goldstein R. An epidemic of Burkholderia cepacia transmitted between patients with and without cystic fibrosis. J Infect Dis 1999, 179:1197-205. 10.1086/314699, 10191223.
10. Chen JS, Witzmann KA, Spilker T, Fink RJ, LiPuma JJ. Endemicity and intercity spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001, 139:643-649. 10.1067/mpd.2001.118430, 11713440.
11. Golini G, Cazzola G, Fontana R. Molecular epidemiology and antibiotic susceptibility of Burkholderia cepacia -complex isolates from an Italian cystic fibrosis centre. Eur J Clin Microbiol Infect Dis 2006, 25:175-180. 10.1007/s10096-006-0099-x, 16501927.
12. McGowan JE. Resistance in nonfermenting gram-negative bacteria: multidrug resistance to the maximum. Am J Infect Control 2006, 34(Suppl 1):S29-S37. 10.1016/j.ajic.2006.05.226, 16813979.
13. Feher M, Schmidt JM. Property distributions: differences between drugs, natural products, and molecules from combinatorial chemistry. J Chem Infect Comput Sci 2003, 43:218-227.
14. Shu Y-Z. Recent natural products based development: A pharmaceutical industry perspective. J Nat Prod 1998, 61:1053-1071. 10.1021/np9800102, 9722499.
15. Demain AL. Pharmaceutically active secondary metabolites of microorganisms. Appl Microbiol Biotechnol 1999, 52:455-463. 10.1007/s002530051546, 10570792.
16. Hawksworth DL. The magnitude of fungal diversity: the 1.5 million species estimate revisited. Mycol Res 2001, 105:1422-1432.
17. Coenye T, LiPuma JJ. Multilocus restriction typing: A novel tool for studying global epidemiology of Burkholderia cepacia. complex infection in cystic fibrosis. J Infect Dis 2002, 185:1454-1462. 10.1086/340279, 11992281.
18. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing, 16th informational supplement. NCCLS document M100-S16. National Committee for Clinical Laboratory Standards, Wayne, PA 2006, Clinical and Laboratory Standards Institute.
19. Hathaway WE, Newby LA, Githens JH. The acridine orange viability test applied to bone marrow cells. I. Correlation with trypan blue and eosin dye exclusion and tissue culture transformation. Blood 1964, 23:517-525.
20. Talbot GH, Bradley J, Edwards JE, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006, 42:657-668. 10.1086/499819, 16447111.
21. Doi Y, Husain S, Potoski BA, McCurry KR, Paterson DL. Extensively drug-resistant Acinetobacter baumannii. Emerg Infect Dis 2009, 15:980-982. 10.3201/eid1506.081006, 2727341, 19523312.
22. Bush K. Why it is important to continue antibacterial drug discovery. ASM News 2004, 70:282-287.
23. DiMasi JA. New drug development in the United States from 1963 to 1999. Clin Pharmacol Ther 2001, 69:286-296. 10.1067/mcp.2001.115132, 11371996.
24. Shlaes DM, Projan SJ, Edwards JE. Antibiotic discovery: state of the state. ASM News 2004, 70:275-281.
25. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev 2007, 6:29-40.
26. Pfister JR. Isolation and bioactivity of 2-aminoquinoline from Leucopaxillus albissimus. J Nat Prod 1988, 51:969-970.
27. Arai I, Nakayama I. Antibacterial properties of pyridine and quinoline-N-oxide derivatives. J Pharm Soc Jpn 1952, 72:167-172.
28. LiPuma JJ, Rathinavelu S, Foster BK, Keoleian JC, Makidon P, Kalikin LM, Baker JR. In vitro activity of a novel nanoemulsion against Burkholderia and other multi-drug resistant cystic fibrosis-associated bacterial species. Antimicrob Agents Chemother 2009, 53:249-255. 10.1128/AAC.00691-08, 2612147, 18955531.
29. Mahenthiralingam E, Baldwin A, Dowson CG. Burkholderia cepacia complex bacteria: opportunistic pathogens with important natural biology. J Appl Microbiol 2008, 104:1539-1551. 10.1111/j.1365-2672.2007.03706.x, 18217926.
30. Sader HS, Jones RN. Antimicrobial susceptibility of uncommonly isolated non-enteric gram-negative bacilli. Int J Antimicrob Agents 2005, 25:95-109. 10.1016/j.ijantimicag.2004.10.002, 15664479.
31. Jiang J, Hoang M, Young JR, Chaung D, Eid R, Turner C, Lin P, Tong X, Wang J, Tan C, Feighner S, Palyha O, Hreniuk DL, Pan J, Sailer AW, MacNeil DJ, Howard A, Shearman L, Stribling S, Camacho R, Strack A, Ploeg LH, Goulet MT, DeVita RJ. 2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists. Bioorg Med Chem Lett 2006, 16:5270-5274. 10.1016/j.bmcl.2006.08.006, 16919456.
32. Ulven T, Little PB, Receveur JM, Frimurer TM, Rist O, Nørregaard PK, Högberg T. 6-Acylamino-2-amino-4-methylquinolines as potent melanin-concentrating hormone 1 receptor antagonists: structure-activity exploration of eastern and western parts. Bioorg Med Chem Lett 2006, 16:1070-1075. 10.1016/j.bmcl.2005.10.066, 16289819.